Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Feng, Hao ^a   Hu, Gui Qiu ^b,c   Wang, Hua Lei ^a   Liang, Meng ^b   Liang, Hongru ^a   Guo, He ^b   Zhao, Pingsen ^d   Yang, Yu Jiao ^b   Zheng, Xue Xing ^a   Zhang, Zhi Fang ^e   Zhao, Yong Kun ^a   Gao, Yu Wei ^a   Yang, Song Tao ^a   Xia, Xian Zhu ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b JILIN UNIVERSITY   (China)

^c JILIN AGRICULTURAL UNIVERSITY   (China)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^e INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN VP2; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOMBYX MORI; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOG; FELINE PANLEUKOPENIA; FELINE PANLEUKOPENIA VIRUS; HEMAGGLUTINATION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOLECULAR SIZE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PUPA (LIFE CYCLE STAGE); WILD TYPE;

ANIMALS; ANTIBODIES; BLOTTING, WESTERN; BOMBYX; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOG DISEASES; DOGS; ERYTHROCYTES; FLUORESCENT ANTIBODY TECHNIQUE; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION TESTS; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PARVOVIRUS, CANINE; PUPA; RECOMBINATION, GENETIC; SUS SCROFA; VIRAL PROTEINS; VIRAL VACCINES; VIRION; VIRUS ASSEMBLY;

EID: 84898403364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079575     Document Type: Article

References (35)

1. Appel JJG, Scott FW, Carmichael LE (1979) Isolation and immunization studies of a canine parvo-like virus from dogs with haemorrhagic enteritis. Vet Rec 105:156-159.
2. Carmichael LE, Joubert JC, Pollock RV (1980) Haemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res 40:784-791.
3. Muzyczka N, Berns KI (2001) Parvoviridae: The Viruses and Their Replication. In: Knipe, D.M, Howley, P.M (Eds.), Fields Virology 4th ed. Lippincott Williams & Wilkins, Philadephia, PA, pp. 2327-2359.
4. Pollock RV (1982) Experimental canine parvovirus infection in dogs. Cornell Vet 72:103-119.
5. Buonavoglia C, Compagnucci M, Orfei Z (1983) Dog Response to Plaque Variant of Canine Parvovirus. Zentralblatt für Veterinärmedizin Reihe B 30 (1-10):526-531.
6. Chalmers W, Truyen U, Greenwood N, Baxendale W (1999) Efficacy of feline panleucopenia vaccine to prevent infection with an isolate of CPV2b obtained from a cat. Vet Microbiol 69:41-45. (Pubitemid 29428134)
7. Yule TD, Roth MB, Dreier K, Johnson AF, Palmer-Densmore M, et al. (1997) Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease. Vaccine 15:720-729. (Pubitemid 27240488)
8. Truyen U (2006) Evolution of canine parvovirus-a need for new vaccines? Vet Microbiol 117:9.
9. Nathanson N, Langmuir AD (1995) The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 142(2):109-140.
10. Sedlik C, Saron MF, Sarraseca J, Casal I, Leclerc C (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A 94:7503-7508. (Pubitemid 27345345)
11. Woo WP, Doan T, Herd KA, Netter HJ, Tindle RW (2006) Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol 80:3975-3984.
12. Chang S, Sgro J, Parrish C (1992) Multiple amino acids in the capsid structure of canine parvovirus coordinately determine the canine host range and specific antigenic and hemagglutination properties. J Virol 66:6858-6867.
13. Feng H, Liang M, Wang HL, Zhang T, Zhao PS, et al. (2011) Recombinant canine parvovirus-like particles express foreign epitopes in silkworm pupae. Vet Microbiol 154(1-2):49-57.
14. Wu X, Yin Z, Cao C, Huang L, Lu X, et al. (2004) Expression of human VEGF165 in silkworm by using a recombinant baculovirus and its bioactivity assay. J Biotechnol 111(3):253-261. (Pubitemid 38891712)
15. McCance D, Mims C (1977) Transplacental transmission of polyoma virus in mice. Infect Immun 18(1):196-202. (Pubitemid 8203240)
16. Paliard X, Liu Y, Wagner R, Wolf H, Baenzinger J, et al. (2000) Priming of strong, broad, and long-lived HIV type 1 p55gagspecific CD8+ cytotoxic T cells after administration of a virus- like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 16:273-282. (Pubitemid 30111963)
17. Schirmbeck R, Bohm W, Reimann J (1996) Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39(1-2):111-119.
18. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, et al. (2000) Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8t cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 16:273-282. (Pubitemid 30111963)
19. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, et al. (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 100:6753-6758. (Pubitemid 36666652)
20. Maranga L, Cruz PE, Aunins JG, Carrondo MJ (2002) Production of core and virus-like particles with baculovirus infected insect cells. Adv Biochem Eng Biotechnol 74:183-206.
21. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651. (Pubitemid 35340782)
22. Madalinski K, Sylvan SP, Hellstrom U, Mikolajewicz J, Zembrzuska-Sadkowska E, et al. (2001) Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine 20(1-2):92-97. (Pubitemid 32905319)
23. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK (2003) Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 108(3):241-247. (Pubitemid 37117370)
24. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, et al. (2003) Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 100(26):15889-15894. (Pubitemid 38021085)
25. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, et al. (2006) Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 80:9134-9143. (Pubitemid 44362963)
26. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, et al. (2004) Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 82(5):506-516. (Pubitemid 39421060)
27. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, et al. (2006) Baculovirusderived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 80:9134-9143. (Pubitemid 44362963)
28. Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, et al. (2009) Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles. J Virol 83(1):304-313.
29. Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, et al. (2002) Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Res 54(3):189-201. (Pubitemid 34327684)
30. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, et al. (2005) Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 79:7059-7067. (Pubitemid 40677337)
31. Buonaguro L, Devito C, Tornesello ML, Schröder U, Wahren B, et al. (2007) DNA-VLP primeboost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25(32):5968-5977. (Pubitemid 47082465)
32. Antonis AF, Bruschke CJ, Rueda P, Maranga L, Casal JI, et al. (2006) A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 24:5481-5490. (Pubitemid 43831379)
33. Roy P, French T, Erasmus BJ (1992) Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10:28-32.
34. Roy P, Bishop DH, LeBlois H, Erasmus BJ (1994) Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12:805-811. (Pubitemid 24190561)
35. Kato T, Kajikawa M, Maenaka K, Park EY (2010) Silkworm expression system as a platform technology in life science. Appl Microbiol Biotechnol 85:459-470.